Mother-to-child transmission of HBV is the main transmission route of HBV infection in China, and antiviral therapy for pregnant patients is particularly important. Due to the special nature of pregnancy, its antiviral therapy should pay attention to the following issues: 1. Antiviral therapy should be completed before pregnancy as far as possible: Antiviral therapy for patients with chronic hepatitis B in pregnancy should consider the difficult issue of pregnancy safety of antiviral drugs, therefore, patients with fertility requirements The patient should try to carry out effective antiviral treatment before pregnancy, with a view to completing antiviral treatment in the first 6 months of pregnancy. IFN has pregnancy toxicity, and patients with unintended pregnancy during antiviral therapy with IFN need to terminate the pregnancy. Although none of the available nucleoside (acid) analogs have been clinically tested in pregnant patients, numerous studies have demonstrated the safety of LAM and TDF (which are not currently available in China) in pregnant patients. Patients with unplanned pregnancy during antiviral treatment with LAM can continue LAM antiviral treatment with adequate communication with the patient. Patients on antiviral therapy with LdT, ADV and ETV may be considered to switch to LAM to continue antiviral therapy. 3. Antiviral treatment for patients with hepatitis attacks during pregnancy: Pregnant patients with mildly elevated ALT can be closely observed or given temporary liver-protective symptomatic treatment, and then antiviral treatment can be given after delivery. Pregnant patients with more severe liver lesions may be considered for antiviral therapy after full consultation with the patient and signing of informed consent, and LAM may be applied for antiviral therapy. 4, mother-to-child transmission blockade of HBV infection: In children with failed mother-to-child transmission blockade, about 90% of the children have HBeAg-positive mothers. Serum HBV DNA load in pregnant patients is one of the key factors of mother-to-child transmission, and effective antiviral therapy can significantly reduce the incidence of mother-to-child transmission of HBV. Studies have shown that LAM antiviral therapy given after 34 weeks of gestation had similar adverse effects in the drug and control groups, but at 1 year of age, the infant HBeAg detection rate was 18% in the drug group compared to 39% in the control group. Another study of LdT for mother-to-child transmission blockade showed that oral LdT 600 mg/d at 28-32 weeks of gestation significantly reduced HBV DNA load before delivery and reduced infant HBsAg positivity at 7 months (0% vs. 13.3%, p<0.05) in patients compared with the unmedicated group. Therefore, based on the available evidence, mother-to-child transmission blockade can be performed with LAM or LdT at 28-34 weeks of gestation. The discontinuation regimen for patients at the end of pregnancy can be referred to the discontinuation regimen for patients applying immunosuppressive drugs or chemotherapy below. 5. Fertility issues in male patients on antiviral therapy: Male patients on IFN antiviral therapy should not consider pregnancy until 6 months after discontinuation of the drug. For male patients on nucleoside (acid) analogue antiviral therapy, there is no evidence of adverse effects of nucleoside (acid) analogue therapy on sperm and the fetus, and fertility can be considered with adequate communication with the patient.